Immunosuppressive and immunomodulatory therapies in Sjögren's disease: current landscape and future perspectives. (PubMed, Expert Opin Pharmacother) - Sep 14, 2026 - "CAR-T cell therapy application in refractory SjD patients currently represents an emerging, strictly experimental approach requiring rigorous evaluation of safety and long-term feasibility. Ultimately, identifying the most effective therapeutic agents will likely require discovering and implementing biomarkers tailored to specific biological endotypes."
IO biomarker • Journal • Review • Immunology • Sjogren's Syndrome • CD40LG • CTLA4
|